Strides Pharma reported its strongest FY26 performance with revenue at ₹4,858.7 crore and EBITDA margins at 19.0%. Ex-U.S. markets drove growth, while debt reduced. The company also made strategic acquisitions and management changes.
Detailed Coverage
Strides Pharma Achieves Strongest FY26 Performance with Record Revenue and Margins
Strides Pharma Science has reported its strongest financial year performance for FY26, with consolidated revenue reaching ₹4,858.7 crore (₹48,587 Mn), a 6.4% increase year-on-year. The company's EBITDA margins expanded significantly to 19.0%, up from the previous year, indicating improved operational efficiencies. Reader Takeaway: Profitability focus drives record results; Ex-U.S. growth is the key engine. ## What just happened Strides Pharma Science announced its fiscal year 2026 results, showcasing robust financial performance. Consolidated revenue grew to ₹4,858.7 crore, and EBITDA margins expanded to 19.0%. The company's operational profit after tax (PAT) saw a substantial increase of 50.3% to ₹518.1 crore, with operational Earnings Per Share (EPS) rising by 50.0% to ₹56.2. ## Why this matters This strong performance highlights the company's successful strategy of focusing on profitability. The expansion in EBITDA margins suggests better cost management and pricing power. A reduced Net Debt-to-EBITDA ratio to 1.6x from 1.9x indicates improved financial health and deleveraging. ## The backstory While the U.S. market contributed a stable ₹2,489.7 crore in revenue, the Ex-U.S. markets emerged as a significant growth driver, posting a 21% year-on-year increase to ₹2,240.4 crore. This strategic shift towards international markets, coupled with operational improvements, has been central to Strides' recent performance. ## What changes now Strides has acquired branded generic products from Sandoz for Sub-Saharan Africa, aiming to become a top five player in that region. Additionally, it acquired the remaining 50% stake in Neviton Softech Private Limited to bolster its IT capabilities. Management changes include Aditya Arun Kumar moving to a Non-Executive Director role and Venkata Seetharama Raju Pakalapati (Ram) appointed as Executive Director. ## Risks to watch Investors should monitor the integration of the acquired African business and the long-term impact of R&D investments in complex products like nasal sprays and controlled substances. ## Peer comparison While specific peer data for FY26 is not provided in the filing, Strides' focus on expanding Ex-U.S. markets and improving profitability aligns with broader industry trends of seeking growth beyond saturated developed markets. ## Context metrics (time-bound) For FY26, Strides reported consolidated revenue of ₹4,858.7 crore, a 6.4% YoY increase. EBITDA stood at ₹925.3 crore, up 15.3% YoY. Operational PAT was ₹518.1 crore (up 50.3% YoY), and Operational EPS was ₹56.2 (up 50.0% YoY). The Net Debt-to-EBITDA ratio improved to 1.6x from 1.9x. ## What to track next Investors will be keen to see the performance of the newly acquired African product portfolio and the continued growth from Ex-U.S. markets. The company also recommended a final dividend of ₹5 per equity share.
